500 Unicorn Park Drive
Suite 303
Woburn, MA 01801
United States
781 222 9600
https://www.replimune.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 331
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Philip Astley-Sparke F.S.A. | Executive Chairman | 1.07M | N/A | 1971 |
Dr. Sushil Patel Ph.D. | Chief Executive Officer | 665.05k | N/A | 1971 |
Dr. Robert Coffin Ph.D. | Founder, Chief Scientist & Director | 785.89k | N/A | 1965 |
Ms. Emily Luisa Hill | Chief Financial Officer | N/A | N/A | 1980 |
Mr. Andrew Schwendenman | Chief Accounting Officer & Treasurer | N/A | N/A | 1976 |
Mr. Christopher Sarchi | Chief Commercial Officer | N/A | N/A | 1968 |
Dr. Konstantinos Xynos M.B.A., M.D., Ph.D. | Chief Medical Officer | N/A | N/A | 1966 |
Mr. Paul Bullock | Chief Manufacturing Officer & Framingham Site Head | N/A | N/A | N/A |
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Replimune Group, Inc.’s ISS governance QualityScore as of 1 June 2024 is 8. The pillar scores are Audit: 8; Board: 9; Shareholder rights: 8; Compensation: 8.